CD7, human recombinant protein
T-cell antigen CD7, GP40, LEU-9, Tp40, TP41
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P09564 |
---|---|
Concentration | 1 |
Calculated MW | 18.8 kDa (178 aa, 26-180 aa + His tag), confirmed by MALDI-TOF. |
Gene ID | 924 |
---|---|
Gene Symbol | CD7 |
Other Names | T-cell antigen CD7, GP40, LEU-9, Tp40, TP41 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥90% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Sequence | MGSSHHHHHH SSGLVPRGSH MGSAQEVQQS PHCTTVPVGA SVNITCSTSG GLRGIYLRQL GPQPQDIIYY EDGVVPTTDR RFRGRIDFSG SQDNLTITMH RLQLSDTGTY TCQAITEVNV YGSGTLVLVT EEQSQGWHRC SDAPPRASAL PAPPTGSALP DPQTASALPD PPAASALP |
Target/Specificity | CD7 |
Format | Liquid |
Storage | -80°C; 1 mg/ml in 20 mM Tris-HCl buffer (pH 8.0) containing 0.4 M Urea and 10% glycerol. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
T-cell antigen CD7, also known as CD7, is a type I transmembrane glycoprotein that is expressed on pluripotential hemopoietic cells, most human thymocytes and some peripheral blood T cells. The CD7 molecule is absent in a subset of human T cells under certain physiologic conditions. Thus an increase in CD7 negative T cells can be seen in some inflammatory skin disease. Recombinant human CD7 protein, fused to His-tag at N-terminus, was expressed in E.coli.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.